Objective: In this paper, we aimed to evaluate the effect and safety of intravitrealranibizumab with vitrectomy for proliferative diabetic retinopathy (PDR) patients' treatment.
INTRODUCTION
Proliferative diabetic retinopathy (PDR) is a serious blinding disease, which is characterized by vitreous hemorrhage, neovascularization originating from the retina and tractive retinal detachment. Pars plana vitrectomy (PPV) is usually reserved for PDR treatment. However, the PPV shows difficulties in the operation process. Hemorrhage during operation increases the difficulties by extending the operation time and increasing the risk of bleeding post-operation (1).
Furthermore, the bleeding out of the control in surgery may result in operation failure.
Recently, advances have been achieved in exploring the mechanism of DR with the application of molecular biology and cell biology technique. Drugs targeting vitreous concentration of vascular endothelial growth factor (VEGF) rises significantly (2) and provides novel perspective for PDR treatment. Ranibizumab (Lucentis) is a recombinant, humanized, monoclonal antibody Fab that can inhibit the vascular proliferation by targeting VEGF-A.
Intravitreal ranibizumab was firstly used for the treatment of neovascular age-related macular degeneration. The efficacy and safety of intravitreal ranibizumab treatment have been widely validated. It is reported that ranibizumab shows promising ambient effect in the perioperative period of PDR, but the long-term safety remained to be evaluated. For the ambient effect, ranibizumab has been widely used in vitreous body related surgery in clinic.
In this paper, we retrospectively analyzed the 26 PDR patients (29 eyes) admitted to our hospital. The efficacy of vitrectomy combined with intravitreal ranibizumab for PDR patients was evaluated, compared with vitrectomy surgery.
SUBJECTS AND METHODS

Patients
Total 26 cases (29 eyes) diagnosed with proliferative diabetic retinopathy (PDR) between June 1, 2014 and January 1, 2015 were retrospectivelyanalyzed in our study. Patients with FBG (fasting blood-glucose) ≤ 7.8 mmol/L and diagnosed with Type II diabetes mellitus for more than 1 month were included in our work. The ultrasound B-mode scan showed that included patients presented withvitreous hemorrhage, exudative membraneand/ortraction retinal detachment (TRD). For PDR patients without vitreous hemorrhage, hyperplasia and/or TRD were tested by fundus examination.
Best corrected visualacuity (BCVA) for patients was measured at light sense to 0.2. All the subjects were given vitrectomy treatment. 
Groups
The 26 cases were divided into two groups including vitrectomy (PPV) treatment group (n=13/15eyes) and intravitrealranibizumab injection combined with vitrectomy (IVR/PPV) treatment group (n=13/14 eyes). There were 6 males (7 eyes) and 7 females (8 eyes) in PPV group. Patients aging from 37 to 88 years (mean: 59.08±14.17 years) were included in IVR/PPV group, which comprised 6 males (7 eyes) and 7 females (7 eyes). The baseline information for cases were mean diabetes duration=13.85±7.80 (range,5～30), mean preoperativeBCVA (logMAR)=1.59±0.50 (range, 0.7～2.0), mean IOP pre-ranibizumab injection=14.23±3.51 mmHg and the mean IOP pre-vitrectomy was 13.69±2.42mmHg. There was no significant difference in gender(χ 2 =0), age (t=0.41), duration of diabetes(t=0.15) and preoperativeBCVA(t=0.47) between two groups. In addition, no difference was observedbetweenaverageIOP in PPV group and averageIOP pre-ranibizumab injection and pre-vitrectomy (P>0.05).
Ranibizumabintravitreal injection
The patients in IVR/PPV group were given the intravitreal injection of ranibizumab by one skilled physician at 3-7 d before vitrectomy surgery. Before treatment, tropicamide (10ml:50mg, SANTEN OY, JAPAN) was administered to the eyes of patients. Surface anesthesia was performed for patients by Proxymetacaine hydrochloride (15ml:75mg,s.a. ALCON-COUVREUR n.v., Belgium). Then, 5% povidone-iodine was applied for preoperative disinfection ofthe conjunctival sac (500ml: 25mg, Shanghai likang disinfection technology co., LTD, Shanghai, China) with an eye speculum. After the conjunctival sac was washed with normal saline solution, we used forceps to stabilize the eye and made a location 3.5mm behind limbus.
The intravitreal injections of 0.5mg Ranibizumab (0.2ml: 2mg, Novartis Pharma Stein AG, Switzerland) were performed with a 4.5-gauge needle. The needle was visualized inwall of eyeball about 1cm. After the needle was withdrawn, the needle mouth was pressed for a moment and dropped with 5% Povidone-iodine solution, followed by washing with normal saline. Finally, the Rong et al 5 ofloxacin (3.5g: 10.5mg, Shenyang xing qi pharmaceutical co., LTD, Shenyang, China) was instilled in eyes.
Vitrectomy surgery
The vitrectomy surgery was performed by a singlesurgeon with the application of ALCON Accurus 800 vitreous cutting system and Novus Spectra high power 532nm laser system. The patients in both two groups were subjected to 23G pars plana vitrectomy with standard three-port system.
Patients complicated with cataract also underwent the ultrasonic emulsification. The surgical procedures included eliminating vitreous hemorrhage, stripping new tunica vasculosalentis, releasing vitreous traction, returning the retina, a total gas-fluid exchange.
Evaluation
The duration of operation and the use of electrocoagulation was recorded. The complications such as iatrogenicslit pore, blooding in early period of postoperation (within 1 month), blooding in the later period (more than 1 month). BCVA was tested at 6 month after operation.
Statistical analysis
The statistical analysis was performed by SPSSl8.0. All the data were expressed as mean±SD.
Difference between groups were analyzed by t test and Fisher exact test for measurement data and enumeration data, respectively. P≤0.05 was considered to be significant.
RESULTS
Surgery duration
The mean surgery duration in IVR/PPV group was 80±15.08 min, ranging from 105 min to 60 min, while the mean surgery duration in PPV group was 108.07±11.63 min (rang, 93 min-130
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BCVA post-operation
In the follow-up period, the mean BCVA (logMAR) of IVR/PPV group was 0.87±0.50, ranging from 0.3 to 1.7. In PPV group, the BCVA (logMAR) of patients were between 0.7 and 2.0 with mean of 1.37±0.47. The mean BCVA in PPV group was significantly higher than IVR/PPV group (t=2.803, P=0.015) ( Table 1) .
Outcomes
Total 10 patients (11 eyes) with cataract in IVR/PPV group were subjected to ultrasonic emulsification and 11 patients (12 eyes) in PPV group. The 8 eyes in IVR/PPV group were filled with silicone oil, while 15 eyes in PPV group was filled with silicone oil in the operation. In the IVR/PPV group, 1 eyewas subjected to electrocoagulation for excessive bleeding and 7 eyes in PPV group. Iatrogenicslit porewas observed in 1 eye of IVR/PPV group and 8 eyes in PPV group.
In the early postoperative period, 2 eyes in IVR/PPV group suffered recurrent bleeding and 9 eyes in PPV group. In the later period after operation, no recurrent bleeding was observed in IVR/PPV group and total 6 eyes suffered recurrent bleeding in PPV group. The incidence of iatrogenicslit pore, bleeding, recurrent bleeding was significantly lower in IVR/PPV group, compared with PPV group (P<0.05). The frequency of the use of electrocoagulation was significantly decreased in IVR/PPV group, compared with PPV group (P=0.035). Additionally, 3 eyes in PPV group suffered iris neovascular glaucoma within 6 month after operation. All the information was listed in Table   2 .
DISCUSSION
PDR patients are usually companied with the destruction of retinal vessel, retinaischemia, appearance of retina and irisneovascularization that may result in vitreous hemorrhage and tractional retinaldetachment.During the vitrectomy surgery, bleeding is an event attributed to retinal neovascularization and vitreous hemorrhage, which may result in ambiguous operation view and increase the difficulties in surgery. Previous studies showed that retinal neovascularization is the main cause of hemorrhage during operation, which is mediated by the secretion of cytokines caused by retinaischemia. VEGF as the cytokine, plays a potent role in angiogenesis and tunica vasculosa lentis development (3). It is reported that VEGF is overexpressed in the progression and development of DR and is the main pathogenic factor for DR.
The current drugs targeting VEGF mainly include Avastin, Lucentis and Macugen(4).
Lucentis is considered to be the most effect drug and has been approved to be the only drug targeting VEGF for treating the eye diseases by the USA FDA. The efficacy and safety of intravitreal ranibizumab have been proved in treating AMD by a large amount of studies (5).
In our work, 13 cases (14 eyes) in IVR/PPV group were pre-treated by intravitreal ranibizumab and then subjected to vitrectomy. The retina and iris neovascularization was regressed significantly, which obviously reduced the incidence of bleeding and iatrogenicslit pore, frequency of electrocoagulation utilization and surgery duration, compared with PPV group (P<0.05).
Intravitreal ranibizumabsignificantly reduced the iatrogenic injury of retina and hemorrhage during operation and thus increased the probability of surgery success and reduced the incidence of recurrence.
Our data also showed that the incidence of bleeding pre-and post-operation was significantly reduced in IVR/PPV group compared with PPV group. We speculated that In addition, the visual acuity of patients in both two groups were improved significantly after treatment (P<0.05), which suggested that vitrectomy improved the restoration of retina, and facilitate visual acuity increase.
The visual acuity of patients in IVR/PPV group increased significantly compared with PPV group, which might be due to the decreased complications by intravitrealranibizumab. Van Geest et al. (6) suggested that the treatment with drug targeting VEGF was closely associated with the imbalance of connective tissuegrowth factor and VEGF. The clinical study indicated that bevacizumabaggravated the fibrosis and could promote the hyperplasia development. Tolentino (7) reported that ranibizumab injection reduced the inflammation response in eyes, but induced the bleeding and stroke. Sharma et al (8) In conclusion, vitrectomy combined with intravitreal ranibizumab significantly improved the visual acuity and surgery success, and reduced the complications. However, the long-term safety and efficacy of intravitreal ranibizumab needed to be further validated. 
